We now have many drugs to help protect the most vulnerable from becoming seriously ill from COVID.
However, new variants have limited the effectiveness of one group -- monoclonal antibodies. A newly published paper shows the antibodies in convalescent plasma may be a better solution.
Convalescent plasma is taken from the blood of recently infected and fully recovered COVID-19 patients. In many cases, the plasma contains high levels of antibodies against the SARS-CoV-2 virus.
But unlike lab-produced monoclonal antibodies, the antibodies in convalescent plasma can attack a whole host of different proteins on the coronavirus -- making them helpful in preventing hospitalizations.
Watch the video above for the full report.